What is the most recent FDA action on file for ARJOHUNTLEIGH POLSKA Sp. z.o.o.?

April 22, 2026. Argus HQ ingests new FDA enforcement records daily.

Has ARJOHUNTLEIGH POLSKA Sp. z.o.o. had product recalls?

Yes, 1 recall on file. See the full history below for each one.

Is this FDA enforcement data for ARJOHUNTLEIGH POLSKA Sp. z.o.o. official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

How many FDA actions has ARJOHUNTLEIGH POLSKA Sp. z.o.o. had?

Argus HQ has recorded 1 FDA events for ARJOHUNTLEIGH POLSKA Sp. z.o.o.: 0 warning letters, 1 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

ARJOHUNTLEIGH POLSKA Sp. z.o.o. — FDA Enforcement History

FDA action counts

Total FDA actions	1
Warning letters	0
Recalls	1
Approval records	0
Form 483 inspection citations	0
Most recent action	April 22, 2026

In short: Argus HQ has recorded 1 FDA events for ARJOHUNTLEIGH POLSKA Sp. z.o.o.: 0 warning letters, 1 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2026-04-22 to 2026-04-22. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Enforcement history

On 2026-04-22, Argus HQ recorded an FDA recall for ARJOHUNTLEIGH POLSKA Sp. z.o.o., rated "high" severity in Argus HQ's classification: ARJOHUNTLEIGH POLSKA Sp. z.o.o. — Class II recall: Arjo Tenor mobile passive patient lift, Model Numbers KHA1000 US and KHA1010 US. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. ARJOHUNTLEIGH POLSKA Sp. z.o.o. has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

What is the most recent FDA action on file for ARJOHUNTLEIGH POLSKA Sp. z.o.o.?: April 22, 2026. Argus HQ ingests new FDA enforcement records daily.
Has ARJOHUNTLEIGH POLSKA Sp. z.o.o. had product recalls?: Yes, 1 recall on file. See the full history below for each one.
Is this FDA enforcement data for ARJOHUNTLEIGH POLSKA Sp. z.o.o. official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
How many FDA actions has ARJOHUNTLEIGH POLSKA Sp. z.o.o. had?: Argus HQ has recorded 1 FDA events for ARJOHUNTLEIGH POLSKA Sp. z.o.o.: 0 warning letters, 1 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

ARJOHUNTLEIGH POLSKA Sp. z.o.o. — Class II recall: Arjo Tenor mobile passive patient lift, Model Numbers KHA1000 US and KHA1010 US →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: Apr 22, 2026

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). ARJOHUNTLEIGH POLSKA Sp. z.o.o. — FDA Enforcement History. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/arjohuntleigh-polska-sp-z-o-o

MLA

"ARJOHUNTLEIGH POLSKA Sp. z.o.o. — FDA Enforcement History." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/arjohuntleigh-polska-sp-z-o-o.

Chicago

Argus HQ Research. "ARJOHUNTLEIGH POLSKA Sp. z.o.o. — FDA Enforcement History." Digital Empire Holdings LLC. Accessed August 29, 2026. https://argushq.ai/company/arjohuntleigh-polska-sp-z-o-o.

BibTeX

@misc{argushq_argushq_ai_company_arjohuntleigh_polska_sp_z_o_o_2026,
  title = {ARJOHUNTLEIGH POLSKA Sp. z.o.o. — FDA Enforcement History},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/company/arjohuntleigh-polska-sp-z-o-o},
  note = {Accessed: August 29, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗